EKOS ultrasound accelerated infusion catheters deliver thrombolytic drugs to 
targeted locations in the peripheral vasculature for rapid dissolution of blood clots. Ultrasound accelerated thrombolysis uses advanced ultrasound excitation to precondition blood clots for rapid clot removal. “EKOS IT” anywhere in the periphery: Veins, Arteries, through an IVC filter and behind valves.


When a clot forms, plasminogen receptor sites are embedded deep into the fibrin. For the clot to be dissolved, lytic agents must be able to access those receptor sites. But the tightly wound fibrin strands prevent the drug from penetrating, limiting access to receptor sites on the interior of the clot.

The EKOS endovascular device is placed directly into the thrombus, where micro-transducers transmit high frequency, low power sound waves. The ultrasonic energy causes the fibrin strands to thin, exposing plasminogen receptor sites. That makes the thrombus more permeable and allows the lytic to penetrate deeper.

The EKOS drug delivery catheters deliver the lytic drug, while the non-cavitational ultrasound energy gently perfuses the drug deep into the clot, limiting the amount that escapes downstream. In vitro studies confirm that thrombus exposed to ultrasound absorbed 48% more t-PA in one hour, and 84% more in two hours, than thrombus not exposed.

Clinical Benefits

EKOS ultrasonic accelerated thrombolysis offers significant benefits over previously used methods of treatment for thrombus. Unlike systemic anticoagulation therapy, it actually dissolves clots, which most likely reduces the risk of post-thrombotic syndrome. Like catheter-directed thrombolysis, the sophisticated EKOS endovascular device can be placed across the occlusive lesion in minutes, minimizing cath lab time. The ultrasound feature of  EKOS offers significant additional clinical advantages including:

  • Successfully treats thrombi in difficult to reach places, such as behind valves
  • Requires significantly shorter treatment times, typically less than half to one quarter of CDT
  • Uses a lower lytic drug dosage
  • Does not fracture or break the thrombus, hence reducing the risk of distal embolism
  • Does not fracture red blood cells, resulting in no adenosine release and no additional compromise to renal function
  • Results in complete dissolution of obstructive thrombus and requires no follow up afterward with catheter-directed lytic
  • Requires less time in the cath lab and less radiation exposure to lab staff